BCL2 and acute lymphoblastic leukemia: Therefore, the aims of this study were to (i) investigate the benefit of hypomethylating agents for infants with KMT2A-rearranged ALL, (ii) elucidate the effect of these drugs on the methylome, transcriptome and identify their target protein binding landscape and (iii) determine the benefit of adding the selective BCL-2 inhibitor, venetoclax, to treatment for infants with KMT2A-rearranged ALL.